Gregory Kouraklis
Overview
Explore the profile of Gregory Kouraklis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
1612
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vardakostas D, Moustogiannis A, Garoufalia Z, Karatza E, Philippou A, Kouraklis G, et al.
J Pers Med
. 2025 Jan;
15(1).
PMID: 39852206
: There is a growing interest in the research of wound healing mechanisms worldwide. Particular attention has been paid to the expression of tissue remodeling- and inflammation-related factors. Herein, we...
2.
Damaskos C, Psilopatis I, Garmpi A, Dimitroulis D, Nikolettos K, Vrettou K, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201636
Background/aim: Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis...
3.
Damaskos C, Dimitroulis D, Garmpi A, Antoniou E, Kouraklis G, Psilopatis I, et al.
In Vivo
. 2023 Oct;
37(6):2402-2408.
PMID: 37905620
Background/aim: Pancreatic neuroendocrine tumors (PNETs) are pancreatic neoplasms with neuroendocrine features, divided into functioning and non-functioning. The non-functioning PNETs are the largest group, and their morbidity is the result of...
4.
Psilopatis I, Garmpis N, Garmpi A, Vrettou K, Sarantis P, Koustas E, et al.
Anticancer Res
. 2023 Aug;
43(9):3861-3869.
PMID: 37648309
Background/aim: Liver cancer constitutes one of the leading cancers globally. During pregnancy, however, liver cancer is an absolute rarity, with very few cases reported in the international literature. The aim...
5.
Psilopatis I, Damaskos C, Garmpis N, Vrettou K, Garmpi A, Sarantis P, et al.
Int J Mol Sci
. 2023 Aug;
24(15).
PMID: 37569726
Endometrial cancer and uterine sarcoma represent the two major types of uterine cancer. In advanced stages, both cancer entities are challenging to treat and correlate with a meagre survival and...
6.
Psilopatis I, Garmpis N, Garmpi A, Vrettou K, Sarantis P, Koustas E, et al.
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190151
Cervical carcinoma is one of the most common cancers among women globally. Histone deacetylase inhibitors (HDACIs) constitute anticancer drugs that, by increasing the histone acetylation level in various cell types,...
7.
Psilopatis I, Damaskos C, Garmpi A, Sarantis P, Koustas E, Antoniou E, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36769004
Unresectable hepatocellular carcinoma (HCC) is an advanced primary liver malignancy with a poor prognosis. The Food and Drug Administration (FDA) has, to date, approved nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, as...
8.
Garmpi A, Damaskos C, Garmpis N, Kaminiotis V, Georgakopoulou V, Spandidos D, et al.
Med Int (Lond)
. 2023 Jan;
2(4):26.
PMID: 36699507
In diabetes, metabolic dysregulation, caused by hyperglycemia, leads to both structural and functional changes in cardiomyocytes and subsequently leads to the development of cardiomyopathy. Histone deacetylases (HDAC) are enzymes that...
9.
Damaskos C, Garmpis N, Dimitroulis D, Garmpi A, Psilopatis I, Sarantis P, et al.
Int J Mol Sci
. 2022 Nov;
23(22).
PMID: 36430594
Hepatocellular carcinoma (HCC) remains one of the most common malignancies and the third cause of cancer-related death worldwide, with surgery being the best prognostic tool. Among the well-known causative factors...
10.
Garmpis N, Damaskos C, Dimitroulis D, Kouraklis G, Garmpi A, Sarantis P, et al.
J Pers Med
. 2022 Oct;
12(10).
PMID: 36294811
Background/aim: There is a strong association between malignancy and histone deacetylases (HDACs). Histone deacetylase inhibitors (HDACIs) are now being tested as antitumor agents in various clinical trials. We aimed to...